Notes to the Condensed Consolidated Interim Financial Statements of the Bayer Group

Key Data by Segment

Key Data by Segment

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

Q2 2017

Q2 2018

 

Q2 2017

Q2 2018

 

Q2 2017

Q2 2018

 

Q2 2017

Q2 2018

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales (external)

 

4,304

4,217

 

1,542

1,413

 

2,163

3,011

 

450

453

Change1

 

+4.9%

−2.0%

 

−0.7%

−8.4%

 

−14.1%

+39.2%

 

+5.6%

+0.7%

Currency-adjusted change1

 

+4.4%

+2.9%

 

−2.2%

−1.4%

 

−15.8%

+46.4%

 

+4.0%

+7.6%

Intersegment sales

 

11

10

 

4

1

 

8

12

 

1

3

Net sales (total)

 

4,315

4,227

 

1,546

1,414

 

2,171

3,023

 

451

456

EBIT1

 

1,102

1,053

 

195

157

 

117

154

 

107

116

EBIT before special items1

 

1,222

1,109

 

210

156

 

212

434

 

107

119

EBITDA before special items1

 

1,481

1,363

 

314

256

 

317

631

 

116

128

Net cash provided by operating activities

 

528

629

 

297

148

 

1,170

1,653

 

97

88

Depreciation, amortization, impairment losses / loss reversals

 

372

297

 

112

100

 

116

199

 

9

9

Key Data by Segment

 

 

Reconciliation

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Group

 

 

Q2 2017

Q2 2018

 

Q2 2017

Q2 2018

 

Q2 2017

Q2 2018

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2017 figures restated

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales (external)

 

252

378

 

3

9

 

8,714

9,481

Change1

 

−1.6%

+50.0%

 

 

−1.6%

+8.8%

Currency-adjusted change1

 

−0.8%

+52.5%

 

 

−2.7%

+14.6%

Intersegment sales

 

508

624

 

(532)

(650)

 

Net sales (total)

 

760

1,002

 

(529)

(641)

 

8,714

9,481

EBIT1

 

45

24

 

(103)

(153)

 

1,463

1,351

EBIT before special items1

 

58

36

 

(102)

(140)

 

1,707

1,714

EBITDA before special items1

 

118

93

 

(99)

(136)

 

2,247

2,335

Net cash provided by operating activities

 

(74)

24

 

(117)

(302)

 

1,901

2,240

Depreciation, amortization, impairment losses / loss reversals

 

60

57

 

3

4

 

672

666

Key Data by Segment

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

H1 2017

H1 2018

 

H1 2017

H1 2018

 

H1 2017

H1 2018

 

H1 2017

H1 2018

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales (external)

 

8,567

8,292

 

3,143

2,822

 

5,283

5,872

 

890

867

Change1

 

+7.2%

−3.2%

 

+2.3%

−10.2%

 

−3.1%

+11.1%

 

+6.7%

−2.6%

Currency-adjusted change1

 

+5.8%

+2.8%

 

+0.2%

−1.8%

 

−5.4%

+18.4%

 

+4.4%

+5.4%

Intersegment sales

 

21

19

 

9

2

 

16

20

 

2

5

Net sales (total)

 

8,588

8,311

 

3,152

2,824

 

5,299

5,892

 

892

872

EBIT1

 

2,321

2,216

 

473

368

 

1,087

1,046

 

233

245

EBIT before special items1

 

2,477

2,273

 

497

372

 

1,219

1,387

 

233

248

EBITDA before special items1

 

2,983

2,778

 

706

569

 

1,432

1,673

 

251

267

Net cash provided by operating activities

 

1,501

1,861

 

562

321

 

491

950

 

66

101

Depreciation, amortization, impairment losses / loss reversals

 

652

548

 

218

197

 

237

288

 

18

19

Key Data by Segment

 

 

Reconciliation

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Group

 

 

H1 2017

H1 2018

 

H1 2017

H1 2018

 

H1 2017

H1 2018

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2017 figures restated.

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales (external)

 

504

756

 

7

10

 

18,394

18,619

Change1

 

−0.4%

+50.0%

 

 

+3.0%

+1.2%

Currency-adjusted change1

 

+0.6%

+50.3%

 

 

+1.2%

+7.9%

Intersegment sales

 

1,218

1,219

 

(1,266)

(1,265)

 

-

Net sales (total)

 

1,722

1,975

 

(1,259)

(1,255)

 

18,394

18,619

EBIT1

 

19

46

 

(243)

(260)

 

3,890

3,661

EBIT before special items1

 

50

66

 

(240)

(244)

 

4,236

4,102

EBITDA before special items1

 

163

180

 

(234)

(236)

 

5,301

5,231

Net cash provided by operating activities

 

(241)

(219)

 

73

(116)

 

2,452

2,898

Depreciation, amortization, impairment losses / loss reversals

 

113

114

 

6

8

 

1,244

1,174

Compare to Last Year